(NASDAQ: KMDA) Kamada's forecast annual revenue growth rate of 8.8% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Kamada's revenue in 2026 is $196,873,000.On average, 6 Wall Street analysts forecast KMDA's revenue for 2026 to be $12,016,582,325, with the lowest KMDA revenue forecast at $11,425,877,112, and the highest KMDA revenue forecast at $12,511,528,686. On average, 5 Wall Street analysts forecast KMDA's revenue for 2027 to be $13,532,571,877, with the lowest KMDA revenue forecast at $12,910,139,333, and the highest KMDA revenue forecast at $14,027,518,238.
In 2028, KMDA is forecast to generate $14,791,858,480 in revenue, with the lowest revenue forecast at $14,104,817,553 and the highest revenue forecast at $15,414,867,884.